Biofrontera Inc. (NASDAQ:BFRI) Short Interest Up 136.2% in October

Biofrontera Inc. (NASDAQ:BFRI) was the recipient of a significant increase in short interest in the month of October. As of October 15th, there was short interest totalling 473,800 shares, an increase of 136.2% from the September 30th total of 200,600 shares. Approximately 14.5% of the company’s shares are short sold. Based on an average daily volume of 368,100 shares, the days-to-cover ratio is currently 1.3 days.

Analyst Ratings Changes

Separately, Benchmark reissued a “buy” rating and set a $7.00 price target on shares of Biofrontera in a research note on Friday, August 16th.

Biofrontera Trading Down 6.4 %

Shares of Biofrontera stock opened at $0.91 on Friday. Biofrontera has a 12 month low of $0.61 and a 12 month high of $5.28. The stock’s fifty day simple moving average is $1.09 and its 200 day simple moving average is $1.18. The company has a market capitalization of $4.62 million, a PE ratio of -0.07 and a beta of 0.50.

Biofrontera (NASDAQ:BFRI) last posted its quarterly earnings data on Wednesday, August 14th. The company reported ($1.12) EPS for the quarter, beating the consensus estimate of ($1.19) by $0.07. The business had revenue of $7.84 million for the quarter, compared to analysts’ expectations of $9.02 million. Biofrontera had a negative net margin of 38.34% and a negative return on equity of 837.97%. Analysts predict that Biofrontera will post -3.11 EPS for the current fiscal year.

Biofrontera Company Profile

Biofrontera Inc, a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection.